Efficacy and safety of inhaled ambroxol hydrochloride solution in patients with lower respiratory tract infectious diseases: a randomized, double-blind, placebo-controlled, multicentre clinical trial
Inhaled ambroxol is better at ameliorating respiratory symptoms and has comparable safety to placebo in patients with LRTI diseases.
Authors
- Di Wu (ORCID: https://orcid.org/0000-0001-5492-6106)
- Hongmei Yue (ORCID: https://orcid.org/0009-0003-5186-6461)
- Haoyan Wang (ORCID: https://orcid.org/0000-0003-3267-8396)
- Hui Li (ORCID: https://orcid.org/0000-0002-7516-7126)
- Jie Zhang (ORCID: https://orcid.org/0000-0001-7683-3971)
- Xiuhua Fu
- Zhiqiang Qin (ORCID: https://orcid.org/0000-0001-9022-4291)
- Faguang Jin
- Zhaolong Cao
Institutions
- Capital Medical University (CN)
- Second Affiliated Hospital of Jilin University (CN)
- Beijing Friendship Hospital (CN)
- First Hospital of Lanzhou University (CN)
- Inner Mongolia Medical University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12879-025-11194-w
- Citations
- 3
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.49